Dr. Naiyer Rizvi, director of thoracic oncology at CUMC, offers updates on immune checkpoint inhibitors in certain forms of lung cancers.
Columbia engineers and P&S researchers have developed a way to deliver drugs that may provide more effective treatments for many lung diseases.
In Columbia's biomedical engineering department, engineers and physicians work together to solve problems and improve health care.
Four P&S physicians—Joy Vink, Nasir Naqvi, Max O'Donnell, and Sameer Sheth—have been named 2015 Gerstner Scholars.
Precision medicine for lung cancer is now allowing some patients to live for years with advanced disease, and better therapies are in the works.
In clinical trials, two new drugs slowed the loss of lung function in patients with a fatal lung disease, idiopathic pulmonary fibrosis.